Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD226 axis drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD226 (DNAM-1) ECD-Fc / Mutant Protein (wild-type and rs763361 variant available) High purity (>95%), Endotoxin <1 EU/μg. Sequence Verified. HEK293 expressed (native glycosylation). |
View CD226 Products |
| Gene Delivery | CD226 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. >10⁸ TU/mL. |
View CD226 Products |
| Benchmark Ab | Anti-CD226 (Agonist Reference Sequence) Recombinant positive control for functional assays. |
View CD226 Products |
| Validator | CD226 siRNA Set For knockdown verification and specificity controls. |
View CD226 Products |
| TIGIT (Competing Receptor) | TIGIT ECD-Fc / Lentivirus Inhibitory receptor competing for CD155/CD112 binding. Essential for selectivity assays. |
View TIGIT Products |
| CD155 (PVR, Ligand) | CD155 Recombinant Protein High-affinity ligand for CD226 binding and blocking studies. |
View CD155 Products |
| PVRIG (CD112R) | PVRIG ECD-Fc / Lentivirus Competing inhibitory receptor for CD112 (NECTIN2). Counter-screening essential. |
View PVRIG Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval for IND-enabling studies | Human/Mouse/Cyno ortholog CD226 proteins available with >95% purity, Sequence Verified, HEK293 expressed |
| TIGIT/PVRIG counter-screening (subfamily off-target) | Homolog panel proteins (CD226, TIGIT, PVRIG) strictly verified by mass spec for selectivity assays |
| Agonist functional validation requires stable cell lines | High-titer Lentivirus Premade Particles for rapid CD226-expressing reporter cell construction |
| Lack of positive controls for binding assays | Clinical Benchmark Antibodies (agonist reference sequences) included as biosimilar controls |
| False positives in binding assays | Validated siRNA included for CD226-specificity verification via knockdown |
| Glycosylation-dependent ligand binding (CD155/CD112) | HEK293 expressed proteins ensure native glycosylation pattern for accurate binding kinetics |
Live CD226 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Agonist Mechanism Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Molecular Characteristics of CD226
CD226 (DNAM-1) is a transmembrane glycoprotein belonging to the immunoglobulin superfamily, containing two Ig-like C2-type domains (Ig-like C2-type 1 and 2). A key coding variant rs763361 (Gly307Ser) is associated with autoimmune disease susceptibility and may influence receptor function. Understanding these molecular features is critical for designing selective agonists and interpreting clinical data.
Global Clinical Landscape & Future Outlook
The race for CD226-targeted therapeutics represents a strategic pivot in the TIGIT/CD226 immune checkpoint axis. As TIGIT inhibitors face clinical challenges, drug developers are increasingly exploring CD226 agonists as the activating counterpart—activating NK cell and T cell cytotoxicity through the DNAM-1 pathway. Major players are shifting from simple monoclonal agonists to next-generation bispecific formats (CD226 × CD3 or tumor antigens) and engineered CAR-NK constructs. The next wave of R&D focuses on conditional activation mechanisms to prevent systemic immune hyperactivation, while also addressing tumor-induced CD226 downregulation and internalization that can limit TIGIT-blocker efficacy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonist mAb | AstraZeneca, Bristol Myers Squibb, Compugen, Gilead | Solid Tumors (NSCLC, CRC, Melanoma) | Stable CD226-expressing cell lines (Lentivirus required) for NFAT reporter assays; ECD-Fc for ligand competition |
| Bispecific (TIGIT/CD226) | Compass Therapeutics, Roche, Arcus Biosciences | Immuno-oncology, Refractory Solid Tumors | Heterodimer validation and cross-reactivity panels (CD226 vs TIGIT selectivity assays); high-purity cross-reactive Abs |
| CAR-NK / NK Cell Therapy | Academic Institutions, Fate Therapeutics, Nkarta | Hematologic Malignancies | High-titer Lentivirus for primary NK cell transduction; expression validation antibodies; ligand binding assay using native glycosylated CD155/CD112 |